{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"27"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Progressive Disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Objective (Best) response according to RECIST 1.1 criteria.","groups":[{"description":"Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG000","title":"Treatment (Vorinostat)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months","title":"Objective Response According to RECIST 1.1 Criteria","type":"PRIMARY","unitOfMeasure":"Participants"}